News: Portfolio 2009

NICHD/NIH TO CONDUCT CLINICAL STUDY WITH AGILE’S WEEKLY, PROGESTIN-ONLY, CONTRACEPTIVE PATCH

Agile Therapuetics and NICHD Collaboration Intended to Provide Breast Feeding Mothers with Needed Contraceptive Option

Princeton, NJ – March 25, 2009 – Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women’s health products, today announced that it has signed a Clinical Trial Agreement with the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The collaboration agreement is for the clinical study of a progestin-only contraceptive patch, identified by Agile Therapeutics as AG1000, designed to deliver a safer and more convenient method of hormonal contraception for breast feeding mothers and women with contraindications to estrogen. The clinical testing of this first-in-class product will be completed in NICHD’s Contraceptive Clinical Trials Network.

 

Agile Therapuetics’ weekly, progestin-only contraceptive patch will be a significant